Exelixis | EXEL - Net Income

Stock Price
44.94
Daily Change
-0.20 -0.44%
Monthly
3.05%
Yearly
19.74%
Q1 Forecast
42.28

Exelixis reported $193.58M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bayer EUR -963M 764M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Exelixis USD 193.58M 8.73M Sep/2025
Genmab DKK 336M 141M Jun/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR -801M 3.6B Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Xencor USD -6.03M 24.8M Sep/2025